PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Cross-protection induced by a A/MAY/97 Emergency Vaccine Against Heterologous Challenge with a Foot-and-mouth Disease Virus from the A/ASIA/G-VII Lineage
Dekker, A.; Sanz-Bernardo, B.; Singanallur, N.B.; Ludi, A.B.; Horsington, J.; Eblé, P.L.; King, D.P.; Vosloo, W. Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage. Vaccines2020, 8, 24.
Dekker, A.; Sanz-Bernardo, B.; Singanallur, N.B.; Ludi, A.B.; Horsington, J.; Eblé, P.L.; King, D.P.; Vosloo, W. Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage. Vaccines 2020, 8, 24.
Dekker, A.; Sanz-Bernardo, B.; Singanallur, N.B.; Ludi, A.B.; Horsington, J.; Eblé, P.L.; King, D.P.; Vosloo, W. Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage. Vaccines2020, 8, 24.
Dekker, A.; Sanz-Bernardo, B.; Singanallur, N.B.; Ludi, A.B.; Horsington, J.; Eblé, P.L.; King, D.P.; Vosloo, W. Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage. Vaccines 2020, 8, 24.
Abstract
Since 2015, outbreaks of foot-and-mouth disease (FMD) in the Middle East have been caused by a new emerging viral lineage, A/ASIA/G-VII. In-vitro vaccine matching data indicated that this virus poorly matched (low r1-value) with vaccines that were being used in the region as well as most other commercially available vaccines. The aim of this study was to assess the performance of two candidate vaccines against challenge with a representative field virus from the A/ASIA/G-VII lineage. The results from an initial full dose protection study provided encouraging data for the A/MAY/97 vaccine, while the A22/IRQ/64 vaccine only protected 2/7 vaccinated animals. In view of these promising results, this vaccine was tested in a potency test (PD50) experiment in which 5 cattle were vaccinated with a full dose, 5 cattle with a 1/3 dose and 5 cattle with a 1/9 dose of vaccine. Vaccines were prepared as would be done during an emergency vaccination campaign using a double oil emulsion adjuvant. At 21 days post vaccination these vaccinated cattle and 3 control cattle were subsequently challenged intradermolingually with a field isolate from the A/ASIA/G-VII lineage. All cattle from the full vaccine dose, 4 cattle from the 1/3 vaccine dose and 2 cattle from the 1/9 vaccine dose were clinically protected against challenge with FMDV A/ASIA/G-VII, resulting in a heterologous potency of 6.5 PD50/dose. These data support previous studies showing that a high potency emergency vaccine can protect against clinical disease when challenged with a heterologous strain of the same serotype. Not only the r1-value of the vaccine, but also the homologous potency of a vaccine should be taken into account when advising vaccines to control an outbreak.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
,
